disease 3,096 words KG: ent-dise-7738e353
Contents

FTD-ALS Spectrum

Disease Info
ALS incidence1-2 per 100,000 person-years globally
FTD incidence4-15 per 100,000 persons aged 45-64 years
FTD-ALS overlap5-15% of ALS patients have comorbid FTD
Gender distributionMale predominance (1.3-1.5:1 for ALS; 1:1 for FTD)
Age of onsetTypically 50-65 years for both conditions
Normal repeats<30
Pathological repeats>30 (typically 60-1000)
PenetranceAge-dependent, with most carriers developing symptoms by age 80
MechanismsThree proposed pathogenic mechanisms:
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (25)

Cross-Seeding Prevention Strategy
Score: 0.69
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
Cryptic Exon Silencing Restoration
Score: 0.53
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE-TREM2 Interaction Modulation
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Stress Granule Phase Separation Modulators
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Axonal RNA Transport Reconstitution
Score: 0.70
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
RNA Granule Nucleation Site Modulation
Score: 0.66
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.65
pg 1/2Next →

Related Analyses (15)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived

Related Experiments (30)

Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.